

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency

Description

Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency is a rare condition that prevents the body from converting certain fats to energy, particularly during periods without food (fasting).

Signs and symptoms of LCHAD deficiency typically appear during infancy or early childhood. Many affected infants have feeding difficulties, such as an extreme dislike of certain foods or of eating at all (food or feeding aversion), nausea, and vomiting. Other signs and symptoms include lack of energy (lethargy), low blood glucose (hypoglycemia), weak muscle tone (hypotonia), delayed development of milestones, liver problems, and abnormalities in the light-sensitive tissue at the back of the eye (retina). Affected individuals can have impaired vision or difficulty seeing things far away (myopia) or in low light (night blindness). These vision problems worsen over time. Later in childhood, people with this condition may experience muscle pain, breakdown of muscle tissue (rhabdomyolysis), and a loss of sensation in their arms and legs (peripheral neuropathy). Infants and children with LCHAD deficiency are also at risk of serious heart problems, such as a weakened heart (cardiomyopathy) and heart failure; breathing difficulties; coma; and sudden death.

Problems related to LCHAD deficiency can be triggered when the body is under stress, for example during periods of fasting, illnesses such as viral infections, or weather extremes. This disorder is sometimes mistaken for Reye syndrome, a severe disorder that may develop in children while they appear to be recovering from viral infections such as chicken pox or flu. Most cases of Reye syndrome are associated with the use of aspirin during these viral infections.

Frequency

The incidence of LCHAD deficiency is unknown. One estimate, based on a Finnish population, indicates that 1 in 62,000 pregnancies is affected by this disorder. In the United States, the incidence is probably much lower.

Causes

Variants (also known as mutations) in the *HADHA* gene cause LCHAD deficiency. The *HADHA* gene provides instructions for making part of an enzyme complex called

mitochondrial trifunctional protein. This enzyme complex functions in mitochondria, the energyproducing centers within cells. As the name suggests, mitochondrial trifunctional protein contains three enzymes that each perform a different function. This enzyme complex is required to break down (metabolize) a group of fats called long-chain fatty acids. Longchain fatty acids are found in foods such as milk and certain oils. These fatty acids are stored in the body's fat tissues. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.

Variants in the *HADHA* gene that cause LCHAD deficiency disrupt one of the functions of this enzyme complex. These variants prevent the normal processing of long-chain fatty acids from food and body fat. As a result, these fatty acids are not converted to energy, which can lead to some features of this disorder, such as lethargy and hypoglycemia. Long-chain fatty acids or partially metabolized fatty acids may also build up and damage the liver, heart, muscles, and retina. This abnormal buildup causes the other signs and symptoms of LCHAD deficiency.

Learn more about the gene associated with Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency

HADHA

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- 3-hydroxyacyl-CoA dehydrogenase, long chain, deficiency
- LCHAD deficiency
- Long-chain 3-hydroxy acyl CoA dehydrogenase deficiency
- Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
- Long-chain 3-OH acyl-CoA dehydrogenase deficiency
- Trifunctional protein deficiency, type 1

Additional Information & Resources

Genetic Testing Information

 Genetic Testing Registry: Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (https://www.ncbi.nlm.nih.gov/gtr/conditions/C3711645/)

Genetic and Rare Diseases Information Center

 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (https://rarediseases.info. nih.gov/diseases/6867/index)

Patient Support and Advocacy Resources

• National Organization for Rare Disorders (NORD) (https://rarediseases.org/)

Clinical Trials

 ClinicalTrials.gov (https://clinicaltrials.gov/search?cond=%22Long-chain 3-hydroxya cyl-CoA dehydrogenase deficiency%22)

Catalog of Genes and Diseases from OMIM

 LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY (https:// omim.org/entry/609016)

Scientific Articles on PubMed

 PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=%28%28long-chain+3-hydroxyacy I-CoA+dehydrogenase+deficiency%5BTIAB%5D%29+OR+%28LCHAD%5BTIAB%5 D%29%29+AND+english%5BIa%5D+AND+human%5Bmh%5D+AND+%22last+360 0+days%22%5Bdp%5D)

References

- Angdisen J, Moore VD, Cline JM, Payne RM, Ibdah JA. Mitochondrialtrifunctional protein defects: molecular basis and novel therapeutic approaches.Curr Drug Targets Immune Endocr Metabol Disord. 2005 Mar;5(1):27-40. doi:10.2174/ 1568008053174796. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/1577720 2)
- den Boer ME, Wanders RJ, Morris AA, IJIst L, Heymans HS, Wijburg FA.Longchain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation andfollowup of 50 patients. Pediatrics. 2002 Jan;109(1):99-104. doi:10.1542/peds.109.1.99. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/11773547)
- Fahnehjelm KT, Holmstrom G, Ying L, Haglind CB, Nordenstrom A, Halldin M, AlmJ, Nemeth A, von Dobeln U. Ocular characteristics in 10 children with long-chain3hydroxyacyl-CoA dehydrogenase deficiency: a cross-sectional study withlong-term follow-up. Acta Ophthalmol. 2008 May;86(3):329-37. doi:10.1111/j.1600-0420.2007. 01121.x. Epub 2007 Dec 19. Erratum In: Acta Ophthalmol.2008 Jun;86(4):466. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/18162058)

- Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO. Effectsof higher dietary protein intake on energy balance and metabolic control inchildren with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) ortrifunctional protein (TFP) deficiency. Mol Genet Metab. 2007 Jan;90(1):64-9.doi: 10.1016/j.ymgme.2006.08. 002. Epub 2006 Sep 22. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/1699 6288) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2813195/)
- Oey NA, den Boer ME, Wijburg FA, Vekemans M, Auge J, Steiner C, Wanders RJ, Waterham HR, Ruiter JP, Attie-Bitach T. Long-chain fatty acid oxidation duringearly human development. Pediatr Res. 2005 Jun;57(6):755-9. doi:10.1203/01.PDR. 0000161413.42874.74. Epub 2005 Apr 21. Citation on PubMed (https://pubmed.ncbi .nlm.nih.gov/15845636)
- Prasun P, LoPiccolo MK, Ginevic I. Long-Chain Hydroxyacyl-CoA DehydrogenaseDeficiency / Trifunctional Protein Deficiency. 2022 Sep 1. In: Adam MP, FeldmanJ, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors.GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from http://www.ncbi.nlm.nih.gov/books/NBK583531/ Citation on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/36063482)
- Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu RevPhysiol. 2002;64:477-502. doi: 10.1146/annurev.physiol.64.082201.154705. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/11826276)
- Sims HF, Brackett JC, Powell CK, Treem WR, Hale DE, Bennett MJ, Gibson B, Shapiro S, Strauss AW. The molecular basis of pediatric long chain3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fattyliver of pregnancy. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):841-5. doi:10.1073/pnas. 92.3.841. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/7846063) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC42716/)
- Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, Hennermann JB, Karall D, de Klerk H, Knerr I, Koch HG, Plecko B, Roschinger W, Schwab KO, Scheible D, Wijburg FA, Zschocke J, Mayatepek E, WendelU. Management and outcome in 75 individuals with long-chain fatty acid oxidationdefects: results from a workshop. J Inherit Metab Dis. 2009 Aug;32(4):488-97.doi: 10.1007/s10545-009-1125-9. Epub 2009 Apr 29. Citation on PubMed (https:// pubmed.ncbi.nlm.nih.gov/19399638)
- Tyni T, Paetau A, Strauss AW, Middleton B, Kivela T. Mitochondrial fatty acidbetaoxidation in the human eye and brain: implications for the retinopathy oflong-chain 3hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Res. 2004Nov;56(5):744-50. doi: 10.1203/01.PDR.0000141967.52759.83. Epub 2004 Sep 3. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/15347768)
- Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. ActaPaediatr. 1999 Mar;88(3):237-45. doi: 10.1080/08035259950169954. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/10229030)

Last updated January 20, 2023